Product Name :
G6PD activator AG1
Description:
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 µΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.
CAS:
421581-52-4
Molecular Weight:
438.65
Formula:
C24H30N4S2
Chemical Name:
[2-(1H-indol-3-yl)ethyl]({2-[(2-{[2-(1H-indol-3-yl)ethyl]amino}ethyl)disulfanyl]ethyl})amine
Smiles :
C(CNCCSSCCNCCC1=CNC2=CC=CC=C12)C1=CNC2=CC=CC=C12
InChiKey:
AJBHTYKMNQDUAA-UHFFFAOYSA-N
InChi :
InChI=1S/C24H30N4S2/c1-3-7-23-21(5-1)19(17-27-23)9-11-25-13-15-29-30-16-14-26-12-10-20-18-28-24-8-4-2-6-22(20)24/h1-8,17-18,25-28H,9-16H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 µΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.|Product information|CAS Number: 421581-52-4|Molecular Weight: 438.65|Formula: C24H30N4S2|Chemical Name: [2-(1H-indol-3-yl)ethyl]({2-[(2-{[2-(1H-indol-3-yl)ethyl]amino}ethyl)disulfanyl]ethyl})amine|Smiles: C(CNCCSSCCNCCC1=CNC2=CC=CC=C12)C1=CNC2=CC=CC=C12|InChiKey: AJBHTYKMNQDUAA-UHFFFAOYSA-N|InChi: InChI=1S/C24H30N4S2/c1-3-7-23-21(5-1)19(17-27-23)9-11-25-13-15-29-30-16-14-26-12-10-20-18-28-24-8-4-2-6-22(20)24/h1-8,17-18,25-28H,9-16H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 20.{{RITA} MedChemExpress|{RITA} MDM-2/p53|{RITA} Purity & Documentation|{RITA} In Vitro|{RITA} custom synthesis|{RITA} Epigenetics} 83 mg/mL (47.{{Sotrovimab} MedChemExpress|{Sotrovimab} SARS-CoV|{Sotrovimab} Protocol|{Sotrovimab} Description|{Sotrovimab} custom synthesis|{Sotrovimab} Cancer} 49 mM; Need ultrasonic).PMID:24065671 |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|AG1 (50, 100, 250, 500, 750, 1000 nM) of 1 μM increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of AG1 toward G6PD. AG1 (1-5 μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1 mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress. AG1 has no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6-phosphogluconate dehydrogenase (6PGD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1 (ALDH3A1).|Products are for research use only. Not for human use.|
